Hodgkin Lymphoma is a type of cancer that originates in the lymphatic system, a key component of the body’s immune system responsible for fighting infections and maintaining fluid balance. This disease is characterized by the presence of abnormal Reed–Sternberg cells, which are large, atypical lymphocytes found within affected lymph nodes. Research in Hodgkin Lymphoma focuses on understanding the molecular mechanisms that drive lymphocyte transformation, improving diagnostic techniques, and developing advanced treatment strategies that enhance long-term survival.

At global scientific platforms such as an Oncology Conference, researchers and clinicians frequently discuss advances in lymphoma biology, targeted therapy, and immunotherapy approaches. Hodgkin lymphoma accounts for a smaller proportion of lymphoid malignancies compared with non-Hodgkin lymphomas, but it has been extensively studied due to its unique pathological characteristics and high responsiveness to treatment. A closely related term widely used in medical literature is Hodgkin’s Disease, which historically referred to the same condition before modern classification systems standardized the terminology.

Hodgkin lymphoma typically develops when lymphocytes undergo genetic changes that disrupt normal immune cell regulation. These abnormal cells accumulate within lymph nodes and interact with surrounding immune cells, creating a unique tumor microenvironment that supports tumor survival and growth. The disease most commonly affects lymph nodes in the neck, chest, and underarms, although it can spread to other lymphatic tissues and organs.

Patients with Hodgkin lymphoma may experience symptoms such as painless swelling of lymph nodes, persistent fatigue, fever, night sweats, and unexplained weight loss. These symptoms are sometimes referred to as “B symptoms” and can indicate active disease progression. Advances in imaging technologies and molecular diagnostics have significantly improved the ability to detect and stage the disease accurately. Modern treatment approaches often include a combination of chemotherapy, radiation therapy, and targeted immunotherapies, resulting in high cure rates for many patients with Hodgkin lymphoma.